You never want to be caught in a counter trend rally.
The stock is trading near its recent secondary pricing and has very attractive price targets from analysts.
Quite a few stocks are fading right now -- not due to poor fundamentals, but due to lack of buying interest.
All these names look oversold, have good longer-term prospects, are well-funded and have liquid option markets around their equities.
The AZN affair exposes the seedy underbelly of drug manufacturing, and the COVID-19 vaccine is certainly a drug.
Lies, damn lies, and statistics in the vaccine age, as Hong Kong and Macau stop administering the Pfizer/BioNTech drug.
Here's my view on this space and where the money is to be made.
Getting international travel and commerce back on track may hinge on vaccine acceptance.
The market's mood seems to be changing almost daily; he's an approach for how to trade it regardless of how it's feeling on any particular day.
Be careful as we could see a retest of the June low in the weeks ahead.